Birnbaum Mathew R, Ma Michelle W, Casey Michael A, Amin Bijal D, Jacobson Mark, Cheng Haiying, McLellan Beth N
J Drugs Dermatol. 2017 Oct 1;16(10):1047-1049.
Immunotherapy-induced vitiligo is an immune-related adverse event (irAE) observed in metastatic melanoma patients treated with immune checkpoint inhibitors that target the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) pathways. To date, the development of leukoderma, poliosis, and halo nevi during immunotherapy has largely been reported in metastatic melanoma patients. We report a case of immunotherapy-induced leukoderma presenting as halo nevi in a patient with non-small cell lung cancer (NSCLC) treated with atezolizumab, a programmed cell death ligand (PD-L1) antibody. Immunotherapy-induced vitiligo in metastatic melanoma patients may be associated with improved survival, but it remains to be determined whether its occurrence in non-melanoma cancers has the same prognostic significance.
J Drugs Dermatol. 2017;16(10):1047-1049.
.免疫疗法诱发的白癜风是一种免疫相关不良事件（irAE），在接受靶向细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性细胞死亡蛋白1（PD-1）通路的免疫检查点抑制剂治疗的转移性黑色素瘤患者中观察到。迄今为止，免疫疗法期间出现的白斑、白发症和晕痣主要在转移性黑色素瘤患者中报道。我们报告1例接受阿特珠单抗（一种程序性细胞死亡配体（PD-L1）抗体）治疗的非小细胞肺癌（NSCLC）患者出现表现为晕痣的免疫疗法诱发白斑的病例。转移性黑色素瘤患者中免疫疗法诱发的白癜风可能与生存率提高相关，但在非黑色素瘤癌症中其发生是否具有相同的预后意义仍有待确定。
《药物皮肤病学杂志》。2017年；16(10):1047 - 1049。
